Benralizumab for Eosinophilic Gastritis (BEGS)

Phase 2/3 Completed 26 enrolled Children's Hospital Medical Center, Cincinnati AstraZeneca · collab

RandomizedParallel-groupQuadruple-blindTreatment

Summary

A Randomized, Double-Blind, Placebo-Controlled Clinical Trial to Evaluate the Efficacy of Benralizumab (Anti-IL5RA) in Subjects With Eosinophilic Gastritis.

Timeline

Start: 2018-04-23
Primary completion: 2020-06-22
Completion: 2022-01-12

Outcome

Met primary endpoint

registry NUMBER Benralizumab: 77 percentage of participants NCT03473977 ↗

registry analysis (other test); Benralizumab vs Placebo; p = 0.0001; Fisher Exact NCT03473977 ↗

Publications

Kliewer KL, Murray-Petzold C, Collins MH, Abonia JP, Bolton SM, DiTommaso LA, Martin LJ, Zhang X, Mukkada VA, Putnam PE, Kellner ES, Devonshire AL, Schwartz JT, Kunnathur VA, Rosenberg CE, Lyles JL, Shoda T, Klion AD, Rothenberg ME. Benralizumab for eosinophilic gastritis: a single-site, randomised, double-blind, placebo-controlled, phase 2 trial. Lancet Gastroenterol Hepatol. 2023 Sep;8(9):803-815. doi: 10.1016/S2468-1253(23)00145-0. Epub 2023 Jun 16.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Benralizumab	Monoclonal antibody	30 mg	Subcutaneous